Extensively StudiedHealing & Recovery

Teriparatide

PTH 1-34

PTH(1-34) | Bone-Building Anabolic Peptide

Half-life

~1 hour (subcutaneous); ~5 minutes (intravenous)

Chain length

34 amino acids

Reference frequency

Once daily at same time each day

Research overview

DoseGear research brief

Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.

Mechanism of action

Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an 'anabolic window' where bone formation exceeds resorption. Teriparatide upregulates IGF-1 and FGF2 expression, stimulates bone formation on trabecular and cortical surfaces, and increases bone mineral density through preferential osteoblast stimulation.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Recombinant and synthetic PTH(1–34) medicine.

What it is researched for

Osteoporosis and fracture prevention through intermittent PTH1-receptor stimulation and bone formation.

Research observation window

The source reports fracture outcomes after approximately 20 months; this is not an immediate bone-strength estimate.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Osteoporosis treatment	20 mcg	Once daily	SubQ (thigh or abdomen)

Reference cycle

Maximum 2 years lifetime treatment

Reference storage

Pen: 2-8°C refrigerated, do not freeze; Discard after 28 days

Safety context

Reported side effects

Injection site reactions
Nausea
Headache
Leg cramps
Dizziness
Joint pain

Contraindications & cautions

Paget's disease of bone
Prior skeletal radiation therapy
History of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy

Scientific references

01
Teriparatide
Scientific citationTeriparatide. StatPearls (NCBI Bookshelf) (2024).
02
The effect of teriparatide therapy on bone density in men with osteoporosis
Scientific citationThe effect of teriparatide therapy on bone density in men with osteoporosis. PubMed (2002).
03
Teriparatide: 2.5 Years of Experience
Scientific citationTeriparatide: 2.5 Years of Experience. Journal of Bone and Mineral Research (2006).
04
Parathyroid Hormone (1-84) and Teriparatide in Postmenopausal Osteoporosis
Scientific citationParathyroid Hormone (1-84) and Teriparatide in Postmenopausal Osteoporosis. Women's Health (2006).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Healing & Recovery